Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Fotemustine (Muphoran (R)) in 22 patients with relapses of high-grade cerebral gliomas
Autore:
Malhaire, JP; Lucas, B; Simon, H; Person, H; Dam-Hieu, P; Labat, JP;
Indirizzi:
CHU, Hop Morvan, Serv Radiotherapie & Oncol Med, F-29609 Brest, France CHU Brest France F-29609 adiotherapie & Oncol Med, F-29609 Brest, France CHU, Hop Cavale Blanche, Serv Neurochirurg, F-29609 Brest, France CHU Brest France F-29609 anche, Serv Neurochirurg, F-29609 Brest, France
Titolo Testata:
BULLETIN DU CANCER
fascicolo: 3, volume: 86, anno: 1999,
pagine: 289 - 294
SICI:
0007-4551(199903)86:3<289:F((I2P>2.0.ZU;2-O
Fonte:
ISI
Lingua:
FRE
Soggetto:
RECURRENT MALIGNANT GLIOMA; PHASE-II TRIAL; CENTRAL NERVOUS-SYSTEM; PRIMARY BRAIN-TUMORS; PULMONARY TOXICITY; INTRAVENOUS CARBOPLATIN; SUPRATENTORIAL GLIOMAS; BCNU CHEMOTHERAPY; INTRAARTERIAL; ASTROCYTOMA;
Keywords:
chemotherapy; fotemustine; relapse; malignant brain tumors;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
52
Recensione:
Indirizzi per estratti:
Indirizzo: Malhaire, JP CHU, Hop Morvan, Serv Radiotherapie & Oncol Med, F-29609 Brest, France CHU Brest France F-29609 & Oncol Med, F-29609 Brest, France
Citazione:
J.P. Malhaire et al., "Fotemustine (Muphoran (R)) in 22 patients with relapses of high-grade cerebral gliomas", B CANCER, 86(3), 1999, pp. 289-294

Abstract

Fotemustine is a third-generation nitrosourea characterized by a phosphoalanine carrier group grafted onto the nitrosourea radical which gives it a high lipophilicity and a better penetration through the cell membrane Between September 1988 and December 1997 22 patients with inoperable or incompletely resected recurrent high-grade gliomas of the brain wee treated at the University Hospital in Brest (France). Treatment consisted of three weekly infusions of fotemustine (100 mg/m(2) days 1, 8 and 15). If patients responded or were stabilized fotemustine was continued at the same dose, but everythree weeks only. Four patients responded to the treatment (18%), while 6 were stabilized (32%). Main toxicity was haematologic ((leucopenia and above all thrombocytopenia); treatment war only interrupted in one patient for leucothrombopenia, and there uas no toxic death. Medium duration of response and/or stabilisation was 6.5 months, and median survival 9.4 months in responding and/or stabilized patients, while it was only 5.0 months if tumourprogressed under chemotherapy (median survival for all patients: 7.5 months). Besides, there was a difference in survival in favour of the young patients (< 50 years-median survival = 11.8 months) in comparison with patientsbetween 50 and 60 years (median survival = 6.8 months; p = 0.0282) or elderly patients > 60 years-median survival = 5.8 months; p = 0.0634). In our series, we did not found any difference in survival according to the initialperformance status of patients before treatment Therefore, fotemustine seems to represent an interesting well-tolerated treatment possibility in patients with inoperable recurrent malignant gliomas of the brain.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 13:33:10